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Background: Polycystic ovarian syndrome (PCOS) is a spectrum of heterogeneous disorders of reproduction and
metabolism in women with potential systemic sequel such as diabetes and obesity. Although, PCOS is believed to
be caused by genetic abnormalities, the genetic background that can be associated with PCOS phenotypes remains
unclear due to the complexity of the trait. In this study, we used a rat model which exhibits reproductive and
metabolic abnormalities similar to the human PCOS to unravel the molecular mechanisms underlining this complex
syndrome.
Methods: Female Sprague–Dawley rats were randomly assigned to DHT and control (CTL) groups. Rats in the DHT
group were implanted with a silicone capsule continuous-releasing 83 μg 5α-dihydrotestosterone (DHT) per day for
12 weeks to mimic the hyperandrogenic state in women with PCOS. The animals were euthanized at 15 weeks of age
and the pairs of ovaries were excised and the ovarian cortex tissues were used for gene expression analysis. Total RNA
was from the ovarian cortex was amplified, labeled and hybridized to the Affymetrix GeneChip® Rat Genome 230 2.0
Array. A linear model system for microarray data analysis was used to identify genes affected in DHT treated rat ovaries
and the molecular pathway of those genes were analyzed using the Database for Annotation, Visualization and
Integrated Discovery (DAVID) analysis tool.
Results: A total of 573 gene transcripts, including CPA1, CDH1, INSL3, AMH, ALDH1B1, INHBA, CYP17A1, RBP4, GAS6,
GAS7 and GATA4, were activated while 430 others including HSD17B7, HSD3B6, STAR, HMGCS1, HMGCR, CYP51,
CYP11A1 and CYP19A1 were repressed in DHT-treated ovaries. Functional annotation of the dysregulated genes
revealed that biosynthesis and metabolism of steroids, cholesterol and lipids to be the most top functions enriched
by the repressed genes. However, cell differentiation/proliferation, transcriptional regulation, neurogenesis, cell
adhesion and blood vessel development processes were enriched by activated genes.
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Conclusion: The dysregulation of genes associated with biosynthesis and metabolism of steroids, cholesterol and
lipids, cell differentiation/proliferation in DHT- treated ovaries could be a molecular clue for abnormal steroidogenesis,
estrous cycle irregularity, abnormal folliculogenesis, anovulation and lipid metabolism in PCOS patients.
Keywords: Polycystic ovarian syndrome, Anovulation, Gene expression, OvaryIntroduction
The ovary is a key organ in the female reproductive
system and its malfunction due to endocrine abnor-
malities could result in female infertility. Polycystic
ovarian syndrome (PCOS) is one of the common
hormonal and metabolic disorders in women of repro-
ductive age [1]. However, due to its heterogeneity and
complexity, universally accepted clinical definition of
PCOS remains ambiguous [2,3]. Indeed, the presence
of polycystic ovarian morphology is one of the com-
mon phenomena that can occur in the majority of
PCOS patients. About 95% of women with PCOS at
their early follicular phase could have polycystic ovar-
ies and reduced level of follicle stimulating hormone
[4] which may lead to antral follicle growth arrest and
increased luteinizing hormone level [5]. In addition,
PCOS is also associated with hyperandrogenism, men-
strual dysfunction, oligo-ovulation and insulin resist-
ance [6]. In this context, PCOS is considered as a
complex androgen excess accompanied by different
degrees of gonadotropic and metabolic dysregulation
controlled by multiple gene interaction and environ-
mental factors [7]. However, to what extent this trait is
transmitted to the next generation and the intrinsic
molecular factors underlining the occurrence of PCOS
is unclear.
Although, the genetic basis of abnormal follicular de-
velopment, anovulation, metabolic disorder and other
heterogenous clinical abnormalities of PCOS patients
seems to require detailed investigation, it is suggested
that daughters from women exhibiting a characteristics
of PCOS could have a higher chance of acquiring
hyperandrogenism and other PCOS phenotypes [8].
Moreover, single nucleotide polymorphism in thyroid
adenoma associated (THADA), DENN/MADD domain
containing 1A (DENND1A), interleukin 6 (IL6) and adi-
ponectin genes has been suggested to be the genetic
causes of PCOS [9-11]. In addition, in vitro studies also
showed altered expression of CYP11A and CYP17 genes
in theca cell derived from PCOS woman [12]. Further-
more, changes in the granulosa and theca cell gene expres-
sion have been reported in women with PCOS [13-15].
Although these association studies were performed using
the samples of PCOS patients, the majority of gene
expression studies were based on the cell culture models
which may not necessarily represent and describe thebiological and molecular networks governing its com-
plex phenotype. Indeed, this can in part be due to the
availability and accessibility of the human sample or
small sample size of the study populations [7] and the
complexity of the trait between individuals. However, to
addresse the clinical heterogeneity of PCOS, animal
models have been described to be the best option to
investigate the pathophysiologic mechanisms associ-
ated with the etiology of PCOS [16-21]. Therefore, to
uncover the broad basis of molecular mechanisms
associated with physiological and anatomical changes
induced by PCOS, we generated a rat PCOS model that
exhibit both polycystic ovaries (PCO) and metabolic
abnormalities by implanting silastic capsules contain-
ing 5α-dihydrotestosterone (DHT) into their ovary in
similar way as previously described by others [22].
Using this rat PCOS model that exhibits both polycys-
tic ovaries (PCO) and metabolic abnormalities, we
have previously demonstrated altered expression of 89
miRNAs following chronic androgen treatment [23].
However, the genes that are activated or repressed as
well as their molecular functions, gene networks and
molecular pathways associated with PCOS phenotypes,
remained unclear. Therefore, this study was conducted
to gain insight into the genes that are associated with
follicular arrest, abnormal steroid and metabolite bio-
synthesis and metabolism, insulin resistance and ovar-
ian dysfunction.
Materials and methods
Details of the materials and methods used in the present
study have been described in our previous publication
[23]. Briefly, female Sprague–Dawley rats were randomly
assigned to DHT and control (CTL) groups. Rats in the
DHT group were implanted with a silicone capsule
continuous-releasing 83 μg 5α-dihydrotestosterone (DHT)
per day for 12 weeks to mimic the hyperandrogenic
state in women with PCOS, whose plasma DHT levels
are approximately 1.7-fold higher than those of healthy
control and those in CTL group received empty capsule
[22]. The animals were euthanized at 15 weeks of age,
ovaries were excised and extraneous tissues carefully
removed. Corpus luteum (CL) was present in most of con-
trol rat ovaries while none or very few CL were observed
in DHT-treated rat ovaries. Ovarian cortex tissues were
snap-frozen in liquid nitrogen and stored at −80°C for




Gene symbol Primer 5’ to 3’ bp
NM_012536 CTRB1 F: CTGAAGATCGCACAGGTCTTT 185
R: TCTTGAGGGCATTGTATTTGG
NM_017239 MYH6 F: AAGCTGCAGTTGAAGGTGAAG 214
R: TGGACAGGTTATTCCTCATCG
NM_013085 PLAU F: GAGGGTGCTTGTCCAATATGA 189
R: CAGGAATACACCAGCTTTGCT
NM_207602 ST3GAL6 F: TGCGTATCACAATCTGACTGC 200
R: AATCACCAGGCAGCAACAG
NM_017128 INHBA F: TAGGCAGTCTGAAGACCATCC 199
R: TGAGTGGAAGGAGAGTGAGGA
NM_031558 STAR F: CTCACGTGGCTGCTCAGTAT 221
R: CTTGGCTGAAGGTGAACAGA
NM_017235 HSD17B7 F: CTTTTAGTCCCAGCGAGGAG 188
R: TGGCCCAAACACAAACATAC
NM_138504 OSGIN1 F: CAATCCCTGAGGAGGAAGAG 217
R: CCCCTCTGGTCTATGGCTAC
NM_013413 RLN1 F: CGTTCCCAGAGCTACAACAAC 249
R:CCATTAGCTCCGTATCAGCAG
NM_031144 ACTB F: ACTGGGACGATATGGAGAAGA 202
R:AGAGGCATACAGGGACAACAC
(bp = number of base pairs).
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of DHT-treated rats have been described [23].
Gene expression analysis using GeneChip@rat genome
array
Total RNAs were isolated from 3 independent DHT and
CTL rat ovaries using miRNeasy mini kit (Qiagen, Hilden,
Germany). Genomic DNA contamination was removed
from the RNA samples using TURBO DNA-free™ kit
(Ambion, Foster City, CA). The concentration of the RNA
was analyzed using the Nanodrop 8000 Spectrophotom-
eter (Thermo Fisher Scientific Inc, DE, USA). The RNA
integrity and quality was evaluated using Agilent 2100
Bioanalyzer with RNA 6000 Nano LabChip® Kit (Agilent
Technologies Inc, CA, USA).
RNA amplification
250 ng of total RNAs from DHT-treated or CTL rat
groups in four replicates was amplified and labeled as
per the GeneChip®3’ IVT Express Kit (Affymetrix, CA,
USA). Eukaryotic poly-A RNA control kit (Affymetrix,
CA, USA) was used as a SPIKE-IN control to monitor
the entire target labeling process. Following amplifi-
cation, the biotin labeled amplified RNA (aRNA) was
purified and fragmented. The distribution of aRNA frag-
ments were evaluated using Agilent 2100 bioanalyzer with
RNA 6000 Nano LabChip® Kit (Agilent Technologies
Inc, CA, USA).
Sample hybridization, array washing, staining and scanning
Prior to hybridization, the fragmented and biotin
labelled cRNA from each rat ovary was mixed with
control oligonucleotide B2 (3 nM), 20× eukaryotic
hybridization controls (bioB, bioC, bioD, cre) (Affyme-
trix, CA, USA), 2× hybridization mix and DMSO. The
hybridization cocktail were then incubated at 99°C
(5 min) and subsequently at 45°C (5 min). Each sample
was then transferred to independent GeneChip® Rat
Genome 230 2.0 Array chip. Three biological replicates
and one technical replicate (pool of three biological
replicates) were hybridized for each rat group for 16 h.
The array slides were washed and stained using
the Fluidics Station 450/250 (Affymetrix, CA, USA),
according to the GeneChip® expression user manual
(P/N 702232 Rev. 3). Arrays were scanned with the
GeneChip™ 3000 laser confocal slide scanner (Affyme-
trix, CA, USA) integrated with GeneChip® Operating
System (GCOS).
Array data analysis and visualization
The array data was normalized by integrating the
bioconductor packages (http://bioconductor.org) in R
environment (www.r-project.org), using GC robust
multi-array average analysis [24]. Briefly, the cellintensity (CELL) files were imported into R software
after loading bioconductor packages (http://bioconduc-
tor.org) that suit to the Rat GeneChip affymetrix array.
The normalized data and the CELL files are stored in
the Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/, series entry number
GSM1437398). The linear models for microarray data
analysis system (LIMMA) [25] and the Benjamini–
Hochberg procedure of false discovery rate adjustment
[26] were employed to discriminate the gene expres-
sion profile between the samples. The differentially
expressed genes were tested for their gene ontology
(GO) terms for over- or under-representation, using a
classical hypergeometric test [27]. The molecular path-
way enriched by differentially expressed genes were
obtained from the Kyoto Encyclopedia of Genes and
Genomes (KEGG) and Panther pathway data bases,
using The Database for Annotation, Visualization and
Integrated Discovery (DAVID) analysis tool [28]. The
heatmaps and clustering of differentially expressed genes
were constructed using Bioconductor (http://www.bio-
conductor.org) in R software environment http://
www.r-project.org/ and/or PermutMatrix [29].
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Some of the differentially expressed genes were ran-
domly selected for validation, using SYBR Green based
quantitative real time polymerase chain reaction (qPCR)
and with sequence specific primers designed online
(http://frodo.wi.mit.edu/primer3/; Table 1). The speci-
ficity and identity of each primer pair was confirmed
by sequencing with the GenomeLab™ GeXP Genetic
Analysis System (Beckman Coulter). The mRNA level
was subsequently quantified using the cDNAs obtained
from reverse transcription of total RNA samples used
for microarray study. The qPCR was then performed in
20 μl reaction volume containing iTaq SYBR Green
Supermix with ROX (Bio-Rad laboratories, Munich,
Germany), the cDNA samples of DHT or CTL samples
and the specific forward and reverse primer in the
StepOnePlus™ Real-Time PCR Systems (Applied Biosystems,
Foster City, CA). The presence of specific amplification
was monitored by evaluating the dissociation curve.
The abundance of each transcript was determined using
the comparative threshold cycle (ΔCT) method. Data
were analyzed after normalizing the Ct value of the
target genes against the housekeeping gene β actin (β-
actin). The Student’s t-test or least significant difference
test procedures was employed to detect differences in
mRNA levels between samples. The level of activation
or repression of a gene in DHT relative to CTL was
determined using the formula 2-ΔΔCT. Differences with
p < 0.05 were considered significant.Figure 1 Ovarian transcriptome profile differences between DHT-treated a
symbol) and non-annotated (unknown gene symbol) dysregulated genes i
genes. (C) The heatmap showing the expression pattern of differentially expre
biological replicates in DHT-treated rat groups while CTL represents biolo
was generated using normalized log2 transformed values and the normalized
with red indicating the activated transcript level while the green color showsResults
Ovarian polycystic syndrome is associated with
dysregulation of gene expression
This study was a part of our previously published results
and thus a detailed description of the PCOS phenotypic
data has been provided [23]. The DHT- treated rats had
higher body weight, oestrous cycle irregularity and re-
duced insulin sensitivity. Ovaries from these rats had
lower weight and exhibited absence of corpus luteum,
higher percentage of follicle cysts, relatively thin mem-
brane granulosa and theca hyperplasia. Thus, to unravel
the genes that are abnormally activated or repressed
due to PCOS, the ovarian transcriptome profile of
DHT-treated and CTL rats were compared using the
GeneChip @rat Genome array. The genes of which the
pattern of expression was different between the DHT
and CTL groups were identified by a linear model de-
scribed in the LIMMA pipeline and bioconductor pack-
ages. 1774 of the 31046 gene transcripts available in
GeneChip® Rat Genome 230 2.0 A array showed ≥ 2 fold
change dysregulation in DHT-treated rat ovaries com-
pared to CTL group (data not shown). However, using a
stricter selection criteria (fold change ≥ 2, p ≤ 0.01 and
false discovery rate (FDR) ≤ 10%), a total of 1003 tran-
scripts were dysregulated in DHT-treated compared to
CTL group (Figure 1A and B). Hierarchical clustering of
the dysregulated genes exhibited a similar expression
pattern within biological replicates and distinct differ-
ences between the groups (Figure 1C).nd CTL rat groups. (A) The number of annotated (with known gene
n DHT rat groups. (B) The fold change (FC) distribution of dysregulated
ssed genes within and between biological replicates. DHT represents
gical replicates in rats received an empty silastic capsule. Heatmap
log2 transformed expression values are described by pseudo color scale
repressed expression pattern of a specific gene.
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Following identification of differentially expressed
genes between DHT-treated and CTL groups, the genes
of which their transcript level was significant reduced
by ≥ 2 folds changes in DHT compared to CTL were
considered as repressed genes. However, those genes
which showed by ≥ 2 folds reduction but displayed a
false discovery rate higher that 0.1 were excluded in the
analysis. Based on these stringent criteria, including
123 express sequence tags (ESTs), a total of 430 gene
transcripts were found to be repressed in the DHT-
treated ovaries. Of all the repressed genes, 320 tran-
scripts displayed fold changes between 2 and 5 whereas
the expression level of 110 genes was dysregulated be-
tween 5 and 134 folds in the DHT group. The list and
expression pattern of genes repressed by 11.9 or moreFigure 2 Significantly repressed genes by ≥ 11.9 folds in DHT-treated rat o
fold change (FC) and the false discovery rate of significantly highly repressed
DHT-treated rat groups while CTL represents biological replicates in rats re
transcript level in CTL groups while the green color shows repressed exprfolds are described in Figure 2. Among the top re-
pressed genes, the expression pattern of relaxin 1
(RLN1), Phospholipase A2 (PLA2G1B), x-prolyl amino-
peptidase (XPNPEP2), Alpha-2-macroglobulin (A2M)
and fatty acid binding protein 6 (FABP6) was repressed
by 133.9, 70.6, 61.6, 58 and 45.8 folds, respectively.
In addition, genes involved in steroid and lipid bio-
synthesis and metabolism, including hydroxysteroid
(17-beta) dehydrogenase 7 (HSD17B7), hydroxy-delta-
5-steroid dehydrogenase 3 beta- and steroid delta-
isomerase 6 (HSD3B6), steroidogenic acute regulatory
protein (STAR), 3-hydroxy-3-methylglutaryl-coenzyme
A synthase 1 (HMGCS1), 3-hydroxy-3-methylglutaryl-
coenzyme reductase (HMGCR) and cytochrome P450
(CYP51, CYP11A1, CYP19A1) were repressed in DHT-
treated ovaries.varies. The hierarchical clustering, the expression pattern, the average
genes in DHT treated rat ovaries. DHT represents biological replicates in
ceived an empty silastic capsule. The red color indicates the activated
ession pattern of a specific gene in DHT treated rat ovaries.
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of DHT-treated rats
To understand the biological processes and molecular
function over- or under-represented in ovaries associ-
ated with repressed genes in the DHT-treated rats, the
functional annotation of the repressed genes were inter-
rogated using the DAVID bioinfomatic tool and the re-
sult revealed a total 31 crucial biological processes to be
repressed in DHT-treated ovaries (Additional file 1:
Table S1). Most importantly, closely interlinked biosyn-
thetic and metabolic functions, namely the biosynthesis
and metabolism of sterols/steroids, cholesterol, isopre-
noids and lipids, were the top significant biological pro-
cesses enriched by repressed genes (Figure 3). In
addition, the repressed genes were also found to be
associated with oxidation/reduction, reactive oxygen
species, metabolism and immune processes. Moreover,
categorization of the repressed genes into theirFigure 3 The top biological processes enriched by genes which were repr
D, E, F) describe clusters of genes involved in a particular function describ
normalized log2 transformed values and the normalized log2 transformed e
groups indicating the activated transcript level while the green color in DHT s
biological replicates in DHT-treated ovaries while CTL represents biological repcorresponding activities (molecular functions) revealed
that 28% of them were known to be involved in catalytic
activity, whereas 15% of the repressed genes are asso-
ciated with binding of cofactors, coenzymes, irons,
carbohydrates, SH3 domains, FADs, heparins, glycos-
aminoglycans, NADPs/NADPHs, cholesterols, glucoses,
immunoglobulins and sterols (Figure 4, Additional file 2:
Table S2). Moreover, 34 repressed genes, including IDH1,
ME1, NSDHL, FASN, GPD1, CYBB, FDXR, ALDH3B1 and
ACAD9, are believed to regulate oxidoreductase activity
(Figure 4, Additional file 2: Table S2).
Gene transcripts activated in ovaries of DHT-treated rats
To identify the transcripts activated in rat ovaries by
DHT treatment, genes of which the expression was in-
creased by ≥ 2-fold (p ≤ 0.01, FDR < 0.1) were investi-
gated, using bioinformatic tools and literature mining. A
total of 573 gene transcripts (57.1% of the totalessed in DHT-treated rat ovaries. The heatmaps on the right (A, B, C,
ed by A, B, C, D, E, F on the left. The Heatmaps were generated using
xpression values are described by pseudo color scale with red in CTL
hows the repressed expression pattern of a specific gene. DHT represents
licates in rats which receive an empty silastic capsule.
Figure 4 Molecular functions overrepresented by repressed genes in DHT-treated ovaries.
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treated rats. The list of top activated genes (with ≥ 4 fold
changes) and their expression pattern within and be-
tween biological replicates is provided in Figure 5. The
most activated genes (between 8- and 35-fold change)
include carboxypeptidase A1 (CPA1), chymotrypsino-
gen B1 (CTRB1), myosin heavy chain (MYH6), carboxy-
peptidase A2 (CPA2), dual specificity phosphatase 27
(DUSP27) and cadherin 1 (CDH1). In addition, increased
expression of genes involved in follicular growth and
function was also evident in DHT-treated ovaries,
including, anti-Mullerial hormone (AMH), aldehyde de-
hydrogenase 1B1 (ALDH1B1), inhibins (INHBA, INHBB,
INHA), CYP17A1, retinol binding protein (RBP4), growth
arrest specific (GAS6, GAS7) and GATA binding protein 4
(GATA4).
Molecular functions activated in ovaries of DHT-treated rats
Gene set enrichment analysis showed 18 candidate
biological processes, including cell differentiation/pro-
liferation, transcriptional regulation/gene expression,
neurogenesis, cell adhesion, RNA metabolism, macro-
molecule biosynthesis and blood vessel development
processes to be affected in DHT-treated ovaries due to
gene activation (Figure 6). Moreover, the activated genes
known to be involved in selective and non-covalent
binding of zinc ions, receptors, growth factors, protein
phosphatases, DNA secondary structure and peptideantigens. In addition, some of the activated genes are
known to be involved in growth factor activity, initiating
for cell growth or proliferation and transcription core-
pressor activity (Table 2).Molecular pathways activated or repressed in
DHT-treated rats
In addition to their biological or molecular functions,
an important and significantly dysregulated molecular in-
teractions and relations associated with the activated or
repressed genes were identified using KEGG and Panther
gene enrichment analysis. The studies suggest 19 mole-
cular pathways being affected in DHT-treated group
(Table 3). Among these, cholesterol and trepenoid biosyn-
thesis pathways, citrate cycle, androgen and estrogen me-
tabolism were enriched by repressed genes while several
metabolic pathways including glycolysis/gluconeogenesis,
fatty acid metabolism, pyruvate metabolism, butanoate
metabolism, lysine, leucine, valine and isoleucine degrad-
ation and glutathione metabolic pathways were enriched
by both activated and repressed genes (Table 3).Validation of microarray data using real time quantitative
PCR (qPCR)
To validate the expression data generated by microarray
analysis, the expression level of 5 activated (CTRB1,
MYH6, PLAU, ST3GAL6 and INHBA) and 4 repressed
Figure 5 The hierarchical clustering and expression pattern of highly activated genes in DHT-treated ovaries relative to CTL group. DHT and CTL
on the dendogram represent biological replicates in DHT-treated and CTL rat ovaries, respectively. The Heatmap was generated using normalized
log2 transformed values and the normalized log2 transformed expression values are described by pseudo color scale with red in DHT-treated
group indicating the activated transcript level while the green color in CTL group describes the repressed expression pattern of a specific gene.
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assessed by qPCR. The validation result shows that all
the randomly selected genes displayed a similar trend
to the microarray data, thus confirming the validity of
the microarray results (Table 4).
Discussion
Using a rat PCOS model, we have previously reported
altered ovarian expression pattern of 83 miRNAs follow-
ing DHT treatment [23]. In this study, we investigated
the gene expression profile of the same ovarian samples
and identified 573 activated and 430 repressed gene
transcripts in DHT-treated rats, suggesting the presence
of transcriptome profile dysregulation due to hyperan-
drogenism. In addition, the cellular localization of the
products of the activated or repressed gene showed 180 of
the dysregulated ones were present in the nucleus while
the majority were localized in the cytoplasm (Additionalfile 3: Figure S1), suggesting a possible dysregulation of
genes function associated with specific ovarian subcellular
localization.
The number of dysregulated ovarian genes in the
DHT-treated rats appeared consistent with an earlier re-
port by human ovarian cDNA microarray [30] in which
the number of up-regulated genes (n = 88) was relatively
higher than the down-regulated ones (n = 31) in ovaries of
PCOS women compared to the non-PCOS subjects. How-
ever in another study where the GeneChips HG_U133A
and HG_U133B arrays from Affymetrix used, majority of
the dysregulated genes in PCOS were found to be down-
regulated [31]. Although the reasons for these apparent
discrepancies are not clear, the possibility that this could
be due to the differences in tissue sampling, the micro-
array platform used and the statistical analysis cannot be
excluded. To evaluate whether altered ovarian genes in
DHT-treated rat resemble those of PCOS women, we
Figure 6 The most significantly molecular functions enriched by genes activated in DHT-treated ovaries. The direction of the arrow shows the
significant level of the gene ontology terms. The heatmaps describe the expression pattern of clusters of genes involving in selected functions.
Heatmaps were generated using normalized log2 transformed values and the normalized log2 transformed expression values are described by
pseudo color scale with red in DHT group indicating the activated transcript level while the green color in CTL shows repressed expression pattern of a
specific gene. DHT and CTL on the bottom of the heatmaps represent biological replicates in DHT-treated rat ovaries and rats which receive an empty
silastic capsule, respectively
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reported [31] (http://press.endocrine.org/doi/suppl/10.1210/
me.2004-0074/suppl_file/suppltable1part1me_04_0074.xls)
and noted that 160 dysregulated genes were observed in
ovaries of both DHT-rats and PCOS women (Additional
file 4: Table S3).
In the current study, we have described the key bio-
logical processes, molecular functions and pathways
affected by dysregulated genes in DHT-treated rats.
While the text mining approach would shed light on the
relevance of the dysregulated genes with respect to the
PCOS phenotype, the present global approach involving
pathway analysis and molecular functions provided a
more comprehensive understanding of the potential
genetic mechanism underling PCOS phenotypes. Our
findings also demonstrated ovarian cell type-specific
changes in expression of genes involved in granulosa
cell proliferation and progesterone biosynthesis [AMH,
RBP4 and cytochrome P450s (CYP51, CYP19A1, CYP11A1
and CYP17A1) and dysregulation of the genes associated
with cholesterol biosynthesis and metabolism (acetyl-
CoA acetyltransferases enzymes, ACTAs and HMGCR)
in DHT-treated ovaries. These findings are consistent
with the dependence of granulosa cell progesterone bio-
synthesis on the de novo cholesterol synthesis [32].More importantly, the action of HMGCR is believed to be
the rate limiting step in cholesterol biosynthesis [33,34].
Our present findings suggest that the dysregulation of
the isoprene pathway in cholesterol biosynthesis, leading
to abnormal accumulation of cholesterol precursors in
hyperandrogenic state. Moreover, down-regulation of
cholesterol biosynthesis may limit the amount of choles-
terol influx and in turn affect ovarian cellular functions
including fertility in DHT-treated rats. Here, a series of
the enzymes involving in the conversion of mevalonate
to arnesyl-diphosphate, isoprepene to saquale, and squa-
lene in cholesterol were also repressed in ovaries of
DHT-treated rats (Figure 7).
One of the major functions of the ovary is the produc-
tion of steroid hormone [35]. Here, we identified dysregu-
lation of several genes associated with steroidogenesis in
ovaries of DHT-treated rats, including repression of cyto-
chrome P450s, STAR and 3β-hydroxysteroid dehydroge-
nases (Figure 8). The repression of STAR in DHT-treated
group suggests a reduced level of cholesterol influx for
downstream steroidogenesis. In addition, the down-
regulation of CYP11A1 and CYP19A1 in DHT-treated
ovaries was consistent with our previous publication
showing decreased aromatase expression and estradiol
secretion in granulosa cells from DHT-treated rats [36].
Table 2 List of molecular functions containing genes with
increased level of mRNA in DHT treated compared to CTL
rat groups
Zinc ion binding NR2F2,MAP3K1,PTGR1,CPA1,VEZF1,
ACY3,SLC39A8,CPA2,RBM5,ZFP278,
ZNF574, ZEB2, JARID1A, PHC1,
ZCCHC11, KLF11, ZFPM2, OSR2,
MSL2L1, TRIM37, PAN3, ZC3H11A,
RGNEF, CRYZ, SIVA1, ZFP26, TRIM35,




NR2F2, CITED2, CRYM, ARNT2, NFIA,
NR3C2, BMP2, SMARCD3, RPL7, MYCN,
ZFP278, ZEB2, KLF11, ZFPM2, ARX,
TLE1, FOXP2, ZNF292, GATA4, NR0B1,
RBPJ, MEIS1, HOXD9, CDH1, FOXO1,
TWIST, KLF15
Receptor binding INSL3, INHA, JAK2, AKAP9, CXCL12,
INHBB, ARNT2, INHBA, PENK, BMP2,
SMARCD3, SEMA3C, EPHA4,SEMA6A,




INHA, INHBB, GHR, ARNT2, NR3C2,
SHMT1, INHBA, BMP2, MYH6, MYH7,
RPL7, PON3, GUCY1A3, FOXP2, NR0B1,
MEIS1, ROBO2





SLCO1A4, SLC13A5, SLC1A3, SLC7A5,
SLC7A8
Growth factor binding FGFR2, IGFBP6, CRIM1,HTRA3, CYR61
Insulin-like growth factor
binding
IGFBP6, CRIM1, HTRA3, CYR61
Protein phosphatase
binding
GHR, PHACTR1, JUP, CDH1






















Table 3 List of molecular pathways containing genes with
activated (↑) and repressed (↓) level of mRNA in DHT
treated compared to CTL rat ovary groups
Biosynthesis of steroids ↓CYP51, ↓HMGCR, ↓SQLE, ↓HSD17B7,
↓FDFT1, ↓LSS, MVD, ↓FDPS, ↓IDI1,




↑INHBB, ↑INHBA, ↑AMH, ↑BMP2,




↑CXCL12, ↓THY1, ↓BCAR1, ↓PECAM1,
↓ CXCR4, ↑CLDN11, ↑MYL9, ↓SIPA1
Cholesterol biosynthesis ↓MVD, ↓HMGCR, ↓HMGCS1, ↓FDPS,
↓IDI1, ↓FDFT1




↓PLA2G1B, ↑PLA2G2A, ↓GPD1, ↓CDS1,
↓ PCYT2, ↑ETNK2, ↑CRLS1
Complement and
coagulation cascades








↑JAK2, ↓NFKBIB, ↑IRS3, ↓ACSL3,
↓ADIPOR, ↑STK11
Butanoate metabolism ↓HMGCS1, ↓AACS, ↑ALDH1B1, ↓ACAT2,
↑ACSM5
Terpenoid biosynthesis ↓SQLE, ↓FDFT1, ↓FDPS, ↓IDI1
Ether lipid metabolism ↓PLA2G1B, ↑PLA2G2A, ↑PAFAH1B3,
↑ENPP6
Citrate cycle (TCA cycle) ↓ACLY, ↓IDH1, ↓DLAT, ↓DLST
Androgen and estrogen
metabolism






Glutathione metabolism ↓GPX1, ↓IDH1, ↓GSTT1, ↑GPX7
Lysine degradation ↑ALDH1B1, ↓DLST, ↓ACAT2,
↑MGC109340
Fatty acid metabolism ↑ACSL3, ↓ACAA2, ↑ALDH1B1, ↓ACAT2
Valine, leucine and
isoleucine degradation
↓HMGCS1, ↓ACAA2, ↑ALDH1B1, ↓ACAT2
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steroidogenesis in DHT-treated rats could result in
abnormal sex hormone levels and ultimately PCOS phe-
notypes, including cycle irregularity, abnormal folliculo-
genesis and anovulation.Women with PCOS may have higher abdominal body fat
distribution, due to hyperandrogenism and insulin resist-
ance [37]. This phenomenon may be attributed by in-
creased level of lactate, long-chain fatty acids and
triglyceride [38-40]. We have previously demonstrated that
the rats treated with DHT exhibited higher body weight
compared to control [23]. Although data regarding the total
fat content of the ovary is lacking, examination into the
gene set enrichment analysis revealed 42 genes associated
with lipid metabolism and biosynthesis were repressed in
DHT-treated rats. Among those, 26 genes including acyl-
CoA synthetase and fatty acid synthase are known to be
involved in dual roles of lipid synthesis and metabolism,
while 16 other genes were related only to lipid metabolism.
Table 4 The array and qPCR results for selected differentially expressed genes
Gene name Gene
symbol
Acess. No Array result qPCR result
FC P value FC P value
Chymotrypsinogen b1 CTRB1 NM_012536 20 (↑) 0.00003 27.3 (↑) 0.0023
Myosin, heavy chain 6, cardiac muscle, alpha MYH6 NM_017239 17 (↑) 0.0004 14 0 (↑) 0.06
Plasminogen activator, urokinase PLAU NM_013085 5.37 (↑) 0.0008 5.56 (↑) 0.13
St3 beta-galactoside alpha-2,3-sialyltransferase 6 ST3GAL6 NM_207602 4.9 (↑) 0.0126 5.28 (↑) 0.05
Inhibin beta-a INHBA NM_017128 5.43(↑) 0.002 28.9 (↑) 0.04
Steroidogenic acute regulatory protein STAR NM_031558 14.57 (↓) 0.001 25.5 (↓) 0.0018
Hydroxysteroid (17-beta) dehydrogenase 7 HSD17B7 NM_017235 30.52 (↓) 0.0003 47.67 (↓) 0.006
Oxidative stress induced growth inhibitor 1 OSGIN1 NM_138504 26.98 (↓) 0.000022 21.57 (↓) 0.0047
Relaxin 1 RLN1 NM_013413 133.9 (↓) 0.0014 255.8 (↓) 0.019
FC = Fold change, ↑ and ↓ indicate the activated and repressed genes in DHT treated compared to CTL rat groups, p ≤ 0.05 considered as significant.
Figure 7 The expression pattern of genes involving in cholesterol biosynthesis pathway in DHT-treated rat ovaries. (A) A modified cholesterol
biosynthesis pathway outlined by [51,52] and the intermediate and final products performed by repressed genes in DHT-treated ovaries. The
genes are indicated in green box while the intermediate products are described in white box. (B) The expression pattern of genes involving in
cholesterol biosynthesis in DHT-treated ovaries compared to CTL. FC: The average fold change reduction in DHT compared to CTL. P value: the
significant level. The red color indicates the activated transcript in CTL level while the green color shows the repressed expression pattern of a
specific gene in DHT rat groups.
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Figure 8 The expression pattern of genes involving in sex steroid biosynthesis pathway in DHT-treated rat ovaries. (A) A modified steroid biosyn-
thesis pathway from [53]. The intermediate and final products performed by dysregulated genes in DHT-treated ovaries are indicated in white
box while the number in red or green circle corresponds the genes (enzymes) indicated in Figure B. (B) The heatmap displaying the expression
pattern of repressed and activated genes involving in steroid biosynthesis in DHT compared to CTL. FC indicates the average fold change gene
expression reduction or activation in DHT compared to CTL. P value: the significant levels.
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and metabolism in the DHT group may result in the accu-
mulation of lipid precursors or lack of essential fatty acids
which are required for normal ovarian physiology.
One of the characteristics of PCOS is the presence of
atretic follicles or premature growth arrest without atresia
[41,42]. These phenotypic manifestations could be due to
defects in steroid biosynthesis and energy metabolism. In
line with this notion, excess androgen, luteinizing hor-
mone and insulin are associated with the recruitment of
several but small preovulatory follicles [5]. Indeed, cell
cycle progression and proliferation is thought to be con-
trolled by several regulators [43]. In the current study, a
total of 45 genes that associated with cell proliferation and
differentiation, including AMH and BMP2, were activated
in ovaries of DHT-treated rats (Figure 6). AMH inhibits
primordial follicle recruitment and decreases the sensi-
tivity of growing follicles to FSH [44]. AMH nulls and het-
erozygous mice exhibited early depletion of primordial
follicles [45]. Similarly, it is possible that BMP2 gene
activated in DHT-treated ovaries could participate in
the regulation of folliculogenesis and luteinization by
modulating gonadotropin receptor expression [46]. Acti-
vation of these genes may induce small follicle growth but
dominant follicle growth arrest in DHT-treated rats,
although this possibility needs further investigation.In addition, genes involved in glycolysis/gluconeogene-
sis are also dysregulated by DHT treatment. It is known
that hexokinases (HK1/2) convert glucose to glucose
6-phosphate [47] while pyruvate dehydrogenase complex
component x (PDHX) catalyzes the conversion of pyru-
vate to acetyl coenzyme A [48,49]. In our study, ovarian
HK1, HK2, PDHX and ACSS2 were repressed but FBP2
and ALDH1B1 were activated in DHT-treated rats (Table 3),
further complicating the metabolic disorders in those
groups. This finding is consistent with earlier report
indicating the down-regulation of several genes regulating
glucose synthesis and consumption in PCOS patients [50].
In addition, down-regulation of the oxidative reductase
gene (Figure 3E) and those of citrate acid cycle pathway
(Table 3) adds further evidence for dysregulated energy
metabolism in DHT-treated ovaries.
In conclusion, we have provided detailed evidence for
transcriptome profile changes in a chronically androgen-
ized PCOS rat model. Our data suggest biosynthesis and
metabolism of cholesterol, sterols/steroids, lipids and oxi-
dation/reduction are key molecular functions associated
with repressed gene expression in DHT-treated rats.
On the other hand, cell differentiation/proliferation,
transcriptional regulation, neurogenesis, cell adhesion
and blood vessel development were enriched by
activated genes in this animal model. It is therefore
Salilew-Wondim et al. Journal of Ovarian Research  (2015) 8:24 Page 13 of 14conceivable that these molecular functional alterations
could be a molecular clue for abnormal steroidogenesis,
estrous cycle irregularity, abnormal folliculogenesis,
anovulation, and disorders in carbohydrate regulation
and lipid metabolism occurring in PCOS patients. This
study contributes significantly to our understanding
of the ovarian transcriptome profile and associated
molecular functional alterations in DHT-treated rats, and
provides the basis for future in-depth functional and
mechanistic studies that to shed light on the pathophys-
iologic significance of the current findings in PCOS.Additional files
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